The Expanded Access Program (EAP) is an open-label, multicenter program to:
1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access
to BMN 110 until commercial product is available
2. Collect additional information on the safety and tolerability of BMN 110 administration
in patients with MPS IVA
Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every
week during the program.